Latest News

Category: News

See all

First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent

Clinical, News,

Telix today announces that the first patient has been dosed in its named patient program in Italy for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®). TLX250-CDx is the Company’s investigational non-invasive carbonic anhydrase IX (CAIX) targeting positron emission tomography (PET) imaging agent for clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney...

Read more

QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy

Clinical, News,

QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical...

Read more

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

ASX, News,

Telix today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure...

Read more

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

ASX, News,

Telix today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics...

Read more

Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline

ASX, News,

Telix today announces its financial results for the financial year ended 31 December 2023....

Read more

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

ASX, News,

Telix today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.)...

Read more

Telix Full Year Results 2023 Investor Webcast Notification

ASX, News,

Telix today advises that it will release its full year results and Annual Report for the period ended 31 December 2023 on Thursday 22 February...

Read more

Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)

Clinical, News,

Telix today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA...

Read more

Presentation to J.P. Morgan Healthcare Conference and Q4 Revenue Update

ASX, News,

Telix today advises it is presenting at the 42nd Annual J.P. Morgan Healthcare Conference (8-11 January 2024) in San...

Read more

Appointment of Dr David Cade to Group Chief Medical Officer

ASX, News,

Telix today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational positron emission tomography (PET) imaging...

Read more